Renal Disease
1. Nephrotoxicity associated costs in vancomycin-treated patients in an ITU.
Presented at the 21st International Congress of Chemotherapy, Birmingham, July 1999 and published in the Journal of Antimicrobial Chemotherapy 1999; 44(Suppl A): 79.
2. The cost associated with managing nephrotoxicity among vancomycin-treated patients in an intensive care unit.
Authors: JF Guest, G Roberts, J Baguley, M Palazzo.
Source: British Journal of Intensive Care 2000; May/June:78-86.
3. Cost Effectiveness of Controlled-Release Oxybutynin Compared with Immediate-Release Oxybutynin and Tolterodine in the Treatment of Overactive Bladder in the UK, France and Austria.
Authors: JF Guest, D Abegunde & FJ Ruiz.
Source: Clinical Drug Invesigation 2004; 24 (6): 305-321.
4. Cost of illness analysis of nocturia in Germany, Sweden, and the United Kingdom.
Presented at the 21st Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Washington DC, May 2016
5. Annual direct and indirect costs attributable to nocturia in Germany, Sweden, and the UK.
Author: D Weidlich, FL Andersson, M Oelke, MJ Drake, AF Jonasson, JF Guest.
Source: Eur J Health Econ. 2016; 18(6): 761-771.
6. Impact of Difelikefalin on the Health-Related Quality of Life of Haemodialysis Patients with Moderate-To-Severe Chronic Kidney Disease-Associated Pruritus: A Single-Arm Intervention Trial
Author: J Fotheringham, JF Guest, J Latus, E Lerma, I Morin, T Schaufler, M Soro, S Ständer, S Zeig.
Source: Patient. 2024;17(2):203-213. doi: 10.1007/s40271-023-00668-1
<<< Go Back